Beckman Coulter Life Sciences announced that their Aquios CL flow cytometer has been accepted by the World Health Organization (WHO) Prequalification of In Vitro Diagnostics Programme. It can now be used specifically for the immunologic assessment of patients having, or suspected of having, ... more
Danaher to Acquire Beckman Coulter, Inc. for $6.8 Billion
Danaher Corporation announced that it has entered into a definitive merger agreement with Beckman Coulter, Inc. pursuant to which Danaher will acquire Beckman Coulter by making a cash tender offer to acquire all of the outstanding shares of common stock of Beckman Coulter at a purchase price of $83.50 per share, for a total enterprise value of approximately $6.8 billion, including debt assumed and net of cash acquired.
The Beckman Coulter Board of Directors has unanimously recommended that Beckman Coulter shareholders accept and tender their shares into the offer, which represents a premium of approximately 45% to Beckman Coulter’s closing price on December 9, 2010, the date on which market speculation began regarding a potential sale of the Company. The offer is subject to customary conditions, including tender of a majority of the outstanding shares into the offer (on a fully diluted basis), applicable regulatory approvals and the absence of a material adverse change with respect to Beckman Coulter. The transaction is expected to be completed in the first half of 2011.
Beckman Coulter would become part of Danaher’s Life Sciences & Diagnostics segment, joining Danaher’s Leica, AB Sciex, Radiometer and Molecular Devices businesses.
Danaher’s President and CEO, H. Lawrence Culp, Jr., said, “Beckman Coulter is an iconic company with a great brand, broad reach and technology leadership; well positioned in the markets it serves. Beckman provides an excellent complement to our existing Life Sciences & Diagnostics businesses. Being part of Danaher, Beckman associates will have the opportunity to leverage the power of the Danaher Business System, including the processes by which Danaher accelerates growth through new product innovation and driving sales, marketing and service, as well as its strength in continuously expanding margins.”
- Beckman Coulter
Beckman Coulter Genomic announces accreditation from the College of American Pathologists (CAP). Furthering a long-standing commitment to delivering state-of-the-art sequencing services and high levels of customer satisfaction, the facility in Danvers completed a comprehensive on-site insp ... more
Siemens Healthcare is selling its microbiology business to Beckman Coulter Inc., a wholly owned subsidiary of Danaher Corporation. The activities of the microbiology business include systems for the identification and antibiotic susceptibility testing (ID/AST) of microorganisms. The decisio ... more
High-throughput labs require reliable automation. Learn more how the innovative Biomek i-Series guarantees simple, efficient and flexible workflows more
The automated Biomek i-Series workstations Biomek i5 and Biomek i7 have been designed to optimize dependability and walk-away time in mid- to high-throughput labs. Numerous product innovations have been taking into account to develop a liquid handling workstation, which fits to the users ev ... more
Phenomenex Inc. announced it has signed a definitive agreement to be acquired by Danaher Corporation. Phenomenex will operate as a standalone operating company, retaining the Phenomenex brand, its personnel and site locations. "Phenomenex is a widely recognizable brand that we are proud to ... more
Danaher Corporation announced that it has entered into a definitive merger agreement with Pall Corporation pursuant to which Danaher will acquire all of the outstanding shares of Pall for $127.20 per share in cash, or a total enterprise value of approximately $13.8 billion, including assume ... more
Life Technologies Corporation announced it has signed a definitive agreement to sell its ownership stake in its mass spectrometry business, operated as a joint venture, to Danaher Corporation for $450 million in cash. Danaher has also signed an agreement to acquire Life Technologies’ joint ... more
- 1ZEISS Group expands executive board
- 2Protein-folding simulations sped up
- 3Physicists propose a new method for monitoring nuclear waste
- 4Genetic model identifies primary myelofibrosis outcomes
- 5New brand image for LAUDA
- 6Live-cell microscopy reveals cell migration by direct forces
- 7Imperial and Tsinghua University launch seed fund for 'ambitious collaborations'
- 8First DNA sequence from a single mitochondria